Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival

Malignant pleural mesothelioma is a rare and aggressive malignancy of the pleura correlated with exposure to asbestos, with a medium survival of 11-12 months after diagnosis. A case of a 67-year-old male who had previously worked in the asbestos industry and is a current smoker is reported. The comp...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2012-01, Vol.5, p.231-236
Main Authors: Zarogoulidis, Paul, Mavroudi, Maria, Porpodis, Konstantinos, Domvri, Kalliopi, Sakkas, Antonios, Machairiotis, Nikolaos, Stylianaki, Aikaterini, Tsiotsios, Anastasios, Courcoutsakis, Nikolaos, Zarogoulidis, Konstantinos
Format: Article
Language:English
Subjects:
asbestos
Asbestos industry
Case studies
Chemotherapy
CT imaging
Diagnosis
Dosage and administration
Doxorubicin
Drug therapy
Mesothelioma
Original Research
pegylated liposomal doxorubicin
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant pleural mesothelioma is a rare and aggressive malignancy of the pleura correlated with exposure to asbestos, with a medium survival of 11-12 months after diagnosis. A case of a 67-year-old male who had previously worked in the asbestos industry and is a current smoker is reported. The computed tomography evaluation revealed a right pleural mass with pleural thickening, and the pleural biopsy confirmed a diagnosis of malignant pleural mesothelioma. He was treated with chemotherapy consisting of etoposide, paclitaxel, and pegylated liposomal doxorubicin hydrochloride. After completion of chemotherapy, radiologic evaluation confirmed a reduction of pleural thickening and improvement in his symptoms. A complete presentation of each drug formulation and characteristics are also included in this paper. The patient's follow-up is continuing, and computed tomography reveals stable disease 9 years after initial examination.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S36915